Safety Profile of Glycopyrronium Compared With Once-Daily Indacaterol in Patients With COPD With Moderate-to-Severe Airflow Limitation: The GEM3 Study

被引：0
|
作者：
Mahler, Donald
Gifford, Alex
Satti, Aditi
Jessop, Nicola
Eckert, Joerg H.
D'Andrea, Peter
Banerjee, Rudrani
机构：
[1] Geisel Sch Med Darmouth, Hanover, NH USA
[2] Temple Univ, Coll Med, Philadelphia, PA 19122 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
来源：
CHEST | 2015年 / 148卷 / 04期
关键词：
D O I：
10.1378/chest.2228025
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
734A
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
    Mtibaa, Mondher
    Gupta, Subhajit
    Muthukumar, Madhusubramanian
    Marvel, Jessica
    Kaur, Harneet
    Ishikawa, Ryotaro
    Olivenstein, Ron
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 957 - 967
  • [22] Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
    Anthony D'Urzo
    Gary T Ferguson
    Jan A van Noord
    Kazuto Hirata
    Carmen Martin
    Rachael Horton
    Yimeng Lu
    Donald Banerji
    Tim Overend
    Respiratory Research, 12
  • [23] Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
    D'Urzo, Anthony
    Ferguson, Gary T.
    van Noord, Jan A.
    Hirata, Kazuto
    Martin, Carmen
    Horton, Rachael
    Lu, Yimeng
    Banerji, Donald
    Overend, Tim
    RESPIRATORY RESEARCH, 2011, 12
  • [24] Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
    Buhl, Roland
    Gessner, Christian
    Schuermann, Wolfgang
    Foerster, Karin
    Sieder, Christian
    Hiltl, Simone
    Korn, Stephanie
    THORAX, 2015, 70 (04) : 311 - +
  • [25] Indacaterol 75 μg once daily improves health status in patients with moderate-to-severe COPD: responder analysis
    Mahler, Donald A.
    Dunn, Leonard J.
    Gotfried, Mark H.
    Williams, James
    Lawrence, David
    McBryan, Danny
    PHARMACOTHERAPY, 2012, 32 (10): : E242 - E242
  • [26] Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study
    Kim, Cheong-Ju
    Yoon, Hyoung-Kyu
    Park, Myung-Jae
    Yoo, Kwang-Ha
    Jung, Ki-Suck
    Park, Jeong-Woong
    Lim, Seong Yong
    Shim, Jae Jeong
    Lee, Yong Chul
    Kim, Young-Sam
    Oh, Yeon-Mok
    Kim, Song
    Yoo, Chul-Gyu
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 1589 - 1596
  • [27] Safety Profile of Inhaled Glycopyrronium Twice Daily in Patients With Moderate-to-Severe COPD: Pooled Analysis From Four Clinical Trials
    Kerwin, Edward
    Pedinoff, Andrew
    Miller, S. David
    Franke-Bray, Brigitte
    Di Giovanni, Robert
    Henley, Michelle
    D'Andrea, Peter
    CHEST, 2015, 148 (04)
  • [28] Efficacy and safety of indacaterol 75 μg once daily in patients with moderate-to-severe COPD: pooled analysis of two phase III trials..
    Donohue, James F.
    Siler, Thomas
    Kerwin, Edward M.
    Williams, James
    Kianifard, Farid
    McBryan, Danny
    PHARMACOTHERAPY, 2012, 32 (10): : E242 - E243
  • [29] A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study
    Lehmann, Sverre
    Ringbaek, Thomas
    Lokke, Anders
    Grote, Ludger
    Hedner, Jan
    Lindberg, Eva
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 199 - 210
  • [30] EVALUATION OF THE ANTIHYPERTENSIVE EFFECT AND SAFETY OF ONCE-DAILY ENALAPRIL COMPARED WITH ATENOLOL IN MODERATE-TO-SEVERE ESSENTIAL-HYPERTENSION
    GABRIEL, MA
    TSIANCO, MCC
    KRAMSCH, DH
    MONCLOA, F
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1986, 40 (05): : 883 - 892
12345